Shots:
- Cognition has reported topline P-II (MAGNIFY/COG2201) trial data assessing zervimesine (200mg, QD, PO) vs PBO in adults with GA secondary to dry AMD; trial concluded after enrolling ~100 of 246 planned subjects
- In the trial, nearly 2/3 pts completed 12mos. & 1/3 completed 18mos. of dosing, showing a 28.6% slower GA progression & ~12%, ~16% & 28.2% reductions in mean lesion size at 6, 12 & 18mos., respectively; additional data incl. safety, demographics, plus visual & anatomic results are under analysis. Full Data to be presented in future meetings
- Zervimesine (CT1812) is being developed to slow the progression of Alzheimer’s disease & dementia with Lewy bodies (DLB) by maintaining the function of the sigma-2 receptor & is under evaluation in P-II (START) trial for early Alzheimer’s
Ref: Cognition Therapeutics | Image: Cognition Therapeutics
Related News:- Japan’s MHLW Receives NDA for Conditional Approval of Astellas’ Avacincaptad Pegol to Treat Geographic Atrophy
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click Here for Full Press Release
